Why This U.S.-Based Cannabis Company Should Be on Your Radar

Cresco Labs ORD (CNSX:CL) recently made the biggest acquisition in the history of the U.S. cannabis company. Is it a buy?

edit Jars of marijuana

Image source: Getty Images

It is hard to keep track of the evolving cannabis market. While investors are familiar with most large-cap pot companies (and there aren’t that many), there are many more marijuana firms that are worth serious consideration. Indeed, many smaller cannabis companies are arguably better bargains, all things considered. Let’s turn our attention to Cresco Labs (CNSX:CL), a Chicago-based pot firm you will want to know about.

Making the best of the U.S. market

The U.S. cannabis market is the largest in the world, but since marijuana is still illegal at the federal level, operating in this market is a challenge. However, there are ways for cannabis companies to operate legally within the U.S. Cresco Labs has managed to pull this off as well as almost any of its peers. The Chicago-based company is currently one of the largest of its kind operating in the U.S.

Could Cresco benefit from the growing U.S. market? The company looks well positioned to do so. First, Cresco — whose main focus is on the medical cannabis market — is currently capable of producing close to 150,000 pounds of cannabis per year. With various ongoing expansion projects, though, Cresco is projected to improve its production capacity to over 500,000 pounds by the end of this year (or about 226,797 kilograms).

Cresco’s production capacity (when it reaches its peak) will be very competitive in the industry. Only about a handful of companies would exceed it. Further, the company is making good use of its product. Cresco currently operates 21 dispensaries (and possesses 51 retail dispensary licences). Cresco prides itself on its differentiated products. The company’s branded products command premiums at the point of sale — an important factor that could help Cresco earn higher margins than pot firms that focus mostly on dried cannabis products.

Cresco is getting larger

There at least is one more reason to be giddy about Cresco’s prospects, and it’s a big one.  The company recently announced it was acquiring Origin House, an Ottawa-based cannabis company that happens to be the leader in the booming California pot market. With its nearly 40 million inhabitants, the Golden State is a larger market than all of Canada. Origin House distributes more cannabis product than any of its competitors in the state.

As Cresco already boasts strong operations elsewhere in the U.S., the acquisition of origin House should make the Chicago-based firm an excellent contender to become one of the leading marijuana companies in North America. Once the deal goes through (pending approval from shareholders and the vote should take place in June), it will be the largest acquisition in the history of the U.S. cannabis market. Thus, if Cresco Labs was unknown before, the company will likely become far more popular among investors and analysts.

The bottom line

While Cresco doesn’t get as many mentions as some of its competitors, astute investors looking to benefit from the growing cannabis market should keep the company in their line of sight. With strong and growing operations in the largest market in the world, growing production capacity, and the coming acquisition of Origin House, Cresco’s market position is very competitive. Cresco’s focus on high-margin products could also pay dividends in the long run.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Prosper Bakiny has no position in any of the companies mentioned. 

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »